This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Dec 2013

Global Renal Denervation Market Turns Into Long-Term Opportunity for Medical Device Companies

The global renal denervation market will witness significant growth over the next 6 years, jumping from $15.5 million in 2012 to $171.7 million by 2019, at a Compound Annual Growth Rate (CAGR) of 41%, thanks mainly to the intervention’s expected approval in major countries, says research and consulting firm GlobalData.


The company’s latest report* states that across the 10 major markets (the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India), only the European Union has approved the use of renal denervation. GlobalData predicts that the intervention will be given approval in all of the countries studied by the end of the forecast period.


This, along with a number of other anticipated events, is expected to drive the global procedure volume from approximately 3000 procedures in 2012 to nearly 40,000 by 2019.


Joseph Gregory, GlobalData’s Analyst covering Surgical Devices, says: “Although there has been much enthusiasm for renal denervation since its introduction to the market in 2010, the intervention has been met with considerable barriers to its adoption. As a result of this, the number of global procedure volumes has been coasting in the low thousands, which is expected to continue through 2014.”


Another reason for the low numbers is the utilisation of renal denervation in resistant hypertension only. However, this is expected to change in 2015, when the anticipated CE Mark for the heart failure indication is obtained in Europe. In addition, the uncontrolled hypertension indication is expected to be approved in the US in 2016, with a subsequent CE Mark in 2018.


Still, major market restraints will impede further adoption of renal denervation, including reimbursement and ambulatory blood pressure readings.


Gregory says: “Health insurance agencies want to see long-term clinical trial data from sophisticated studies, but the longest follow-up to date is 3 years in a nonrandomised study. In addition, the purported efficacy results from the majority of company-sponsored clinical trials have recently come into question, given the use of office-based blood pressure measurements rather than ambulatory measurements.”


Compounded with several other market barriers, such as game-changing technologies developed by competitors, renal denervation will have to bear a decade of significant scrutiny before it takes off and sees optimal adoption, according to GlobalData.

*MediPoint: Renal Denervation — Global Analysis and Market Forecasts

Related News